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Liver cirrhosis is one of the most representative forms of
liver ﬁbrosis and represents a serious health problem.
Recently, transplantation of bone marrow-derived cells
including mesenchymal stem cells was reported to reduce
carbon tetrachloride (CCl4)-induced liver ﬁbrosis (Fang
et al. 2004; Sakaida et al. 2004; Wu et al. 2005; Zhao
et al. 2005; Oyagi et al. 2006), while foetal liver epithelial
progenitor cells have also been shown to ameliorate diethy-
lnitrosamine-induced liver ﬁbrosis (Zheng et al. 2006).
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Summary
We transplanted undifferentiated embryonic stem (ES) cells into the spleens of carbon
tetrachloride (CCl4)-treated mice to determine their effects on liver ﬁbrosis. Carbon
tetrachloride at 0.5 ml⁄kg of body weight was injected intraperitoneally into C57BL⁄6
mice twice weekly for up to 20 weeks. Four weeks after the ﬁrst injection, the mice
were divided into two groups and those in group 1 received 1 · 10
5 ES cells genetically
labelled with enhanced green ﬂuorescent protein (GFP) in the spleens, while group 2
mice received 0.1 ml of phosphate-buffered saline. In group 1, GFP-immunopositive
cells were retained and found in areas of ﬁbrosis in the liver, and reduced liver ﬁbrosis
was observed as compared with group 2. Secondary transplantation of ES cells at
12 weeks after the initial transplantation enhanced the reduction in liver ﬁbrosis. No
teratoma formation or uncontrolled growth of ES cells in organs, including the liver
and spleen, was observed in any of the mice. In the livers of group 1 mice, metallopro-
teinase 9-immunopositive cells derived from ES cells as well as those from the recipient
were observed. These cells were also found to be immunopositive for the hepatoblast
marker Delta-like (DlK-1), a member of the DlK-1 family of transmembrane proteins.
These results suggest that ES-based cell therapy is potentially useful for liver ﬁbrosis
treatment and that reduction in CCl4-induced liver ﬁbrosis by transplantation of ES
cells may be related closely to the emergence of metalloproteinase-producing hepato-
blast-like cells.
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ﬁbrosis.
Embryonic stem (ES) cells are self-renewing and pluri-
potent cells derived from the inner cell masses of pre-
implantation blastocysts (Evans & Kaufman 1981; Martin
1981), and are considered to be an optimal source for
cell-replacement therapy, because of their limitless growth
and pluripotent differentiation capacity. We previously
reported the differentiation of mouse ES cells into dopa-
minergic neurons (Nishimura et al. 2003), rhodopsin-
immunopositive photoreceptor-like cells (Sugie et al.
2005), insulin-secreting cells (Shiroi et al. 2002), enteric
smooth muscles (Yamada et al. 2002) and hepatocyte-like
cells (Ishizaka et al. 2002) in vitro. Further, we recently
found that ES cells developed into hepatocyte-like cells
after intrasplenic transplantation in mice that received
short-term treatment with CCl4 (Moriya et al. 2007). In
that study, it was also shown that intrasplenic transplanta-
tion of ES cells reduced ﬁbrosis of the liver at the end of
the 4-week period of CCl4 treatment.
In this study, we transplanted ES cells genetically labelled
with enhanced green ﬂuorescent protein (GFP) into the
spleens of mice under long-term treatment with CCl4 to
examine their potential efﬁcacy toward liver ﬁbrosis. Green
ﬂuorescent protein-immunopositive cells were consistently
found in the areas of ﬁbrosis in the mouse livers and liver
ﬁbrosis was reduced in mice that received ES cells, as com-
pared with those that received phosphate-buffered saline
(PBS). A second intrasplenic transplantation of ES cells at
12 weeks after the initial transplantation enhanced the
improvement of liver ﬁbrosis. Further, metalloproteinase 9
(MMP9)-immunopositive cells derived from ES cells were
found in the livers of group 1 mice, as well as those derived
from the recipients themselves, which were immunopositive
for DlK-1, a hepatoblast marker (Tanimizu et al. 2003).
These results suggest the potential usefulness of ES-based
cell therapy for liver ﬁbrosis and that improvement of CCl4-
induced liver ﬁbrosis by transplantation of ES cells may
be due to the emergence of metalloproteinase-producing
hepatoblast-like cells.
Materials and methods
Murine ES cell line
We utilized G4-2 cells from a mouse ES cell line (129⁄SvJ
mouse ES cells, a kind gift from Dr Hitoshi Niwa, RI-
KEN Center for Developmental Biology, Kobe, Japan),
which carry an enhanced GFP gene under the control of
the CAG expression unit (Niwa et al. 2000). For this
study, undifferentiated G4-2 cells were maintained on gel-
atin-coated dishes without feeder cells in Dulbecco’s
modiﬁed Eagle’s medium (Sigma, St Louis, MO, USA)
supplemented with 10% foetal bovine serum (FBS;
GIBCO⁄BRL, Grand Island, NY, USA), 0.1 mM 2-mercap-
toethanol (Sigma), 10 mM non-essential amino acids
(GIBCO⁄BRL), 1 mM sodium pyruvate (Sigma) and
1400 U⁄ml of leukaemia inhibitory factor (GIBCO⁄BRL).
The G4-2 cells carried the blasticidin S-resistant selection
marker gene driven by the Oct-3⁄4 promoter (active under
undifferentiated status) and were occasionally cultured in
medium containing 10 lg⁄ml blasticidin S to eliminate
differentiated cells.
Preparation of graft cells and transplantation
Culture dishes (9 cm in diameter) were used to maintain the
undifferentiated ES colonies, then washed with 8 ml of ice-
cold PBS (pH 7.4) thrice and treated with 1.0 ml of 0.025%
trypsin⁄PBS for 2 min at 37  C. Five millilitres of ES main-
tenance medium containing 10% FBS was added to each
dish to stop trypsin activity. Single cell solutions were easily
obtained by repeated pipetting. Cells were washed with ice-
cold PBS thrice and ﬁnally prepared for transplantation in a
PBS solution at a cell concentration of 1 · 10
6⁄ml.
Green ﬂuorescent protein-positive undifferentiated ES cells
at 1 · 10
5 (0.1 ml of 1 · 10
6⁄ml solution) were transplanted
into the spleen, using an intrasplenic transplantation proce-
dure previously described (Moriya et al. 2007). Brieﬂy, a 1-
cm incision was made on the left ﬂank and the spleen was
extracted through the incision. Then, 0.1 ml of the graft cell
solution (1 · 10
6 cells⁄ml) was slowly infused into the infe-
rior pole of the spleen using a 31-gauge needle and a Hamil-
ton syringe. Once the infusion was complete, the syringe
was left in place for 1 min.
CCl4 treatment
To induce liver damage, CCl4 at 0.5 ml⁄kg of body weight
was injected into the peritoneum twice a week throughout
the treatment period.
Grouping of animals and outline of experiments
Female C57BL⁄6 mice were purchased from Japan SLC
(Shizuoka, Japan) at 6 weeks of age and used as experi-
mental animals. All procedures including the surgical steps
were performed in accordance with the Guidelines of Nara
Medical University for experiments involving animals and
recombinant DNA.
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4 weeks, after which four were killed and ﬁbrosis of the
livers was examined, with that day was designated as day
0. The remaining 52 were divided into group 1 (n = 28)
and group 2 (n = 24). Group 1 mice received transplanta-
tion of 1 · 10
5 graft cells (0.1 ml of 1 · 10
6⁄ml solution)
on day 0, while group 2 mice were injected with 0.1 ml
of PBS, instead of graft cells. Mice in both groups were
treated with CCl4 twice a week consecutively. Liver sam-
pling was performed after 1, 2, 4, 8 and 12 weeks (W1,
W2, W4, W8 and W12 respectively) using four mice from
each group, as well as on day 1 using group 1 mice only.
In experiment 2, the remaining four mice in group 1
received a second transplantation of graft cells into the
spleen at W12, while those in group 2 received 0.1 ml of
PBS, then both groups continued to receive treatment with
CCl4 for an additional 4 weeks. Animal grouping and an
outline of the experiments are shown in Figure 1.
Tissue preparation
The livers were thoroughly perfused via the heart with 4%
paraformaldehyde to wash out contaminating blood cells.
For ﬁxation, the perfused livers were incubated with 4%
paraformaldehyde overnight and then soaked in 30%
sucrose for 3 days. Tissues were frozen on dry ice and
sectioned into 5-mm slices using a cryostat in preparation
for staining.
Staining for collagen using picro-Sirius red
Frozen tissue sections were desiccated completely, then
washed with distilled water for 5 min and incubated for
40 min in a saturated picric acid aqueous solution (1.1 g
of picric acid in 100 ml distilled water). Next, a 0.1%
concentration of picro-Sirius red powder was mixed into
the solution and tissue sections were additionally soaked
for a few minutes. When the sections were determined to
be properly stained, they were removed, and rinsed twice
in 0.01 N HCl and distilled water. Finally, the sections
were brieﬂy dehydrated with 70% ethanol for 30 s and
100% ethanol for 1 min, ﬁxed with xylene and placed
under coverslips.
Staining for collagen using Mallory-azan
First, frozen tissue sections were desiccated, then incubated
in an azocarmine G aqueous solution (0.1 g of azocarmine
G powder and 1 ml of absolute acetic acid in 100 ml of
distilled water) at 60  C for 60 min and then at room
temperature for 30 min. Next, after rinsing in distilled
water, the tissue sections were soaked in a 5%
molybdenum phosphate aqueous solution overnight, after
which they were rinsed in distilled water, and soaked in
an aniline blue and orange G-mixed aqueous solution
(0.5 g of aniline blue, 2 g of orange G and 8 ml of
absolute acetic acid in 100 ml of distilled water) at room
temperature for 60 min. Finally, the sections were
dehydrated, ﬁxed and placed under coverslips.
Immunohistochemistry of GFP
Frozen tissue sections were desiccated completely, then
washed with PBS and soaked in PBS containing 5%
bovine serum albumin (BSA) for 5 min, after which they
were incubated overnight with anti-GFP (1:1000; Nacalai
Tesque Inc, Kyoto, Japan). The sections were then washed
with PBS and incubated with biotin-conjugated anti-rat
IgG secondary antibodies for 1 h at 37  C (1:200; Vector
Laboratories Inc, Burlingame, CA, USA). Next, for the
purpose of intrinsic peroxidase elimination, the sections
were immersed in 3% hydrogen peroxide (H2O2) for
30 min. The sections were incubated with Vectastain
ABC
  reagent (Vector Laboratories Inc) for 2 h at 37  C,
then treated with 0.02 M Tris–HCl buffer (pH 7.5) con-
taining 4% diaminobenzidine tetrahydrochloride (Vector
Laboratories Inc) in the presence of 0.0004% H2O2 for
2 min at room temperature. Stained sections were rinsed
with distilled water and immersed in ethanol and xylene
for complete dehydration. Finally, the sections were
enclosed with Entellan-new
  (Merck, Tokyo, Japan).
Immunoﬂuorescence analyses
Goat anti-MMP9 (1:100; Santa Cruz Biotechnology Inc,
Santa Cruz, CA, USA), rabbit anti-F4⁄80 (1:100; Santa Cruz
Biotechnology Inc), and either rabbit or rat anti-GFP (1:500;
Molecular Probe Inc, Eugene, OR, USA or Nacalai Tesque
Inc, Kyoto, Japan respectively) were used as primary anti-
bodies. For the secondary antibodies, Alexa Fluor
  546 goat
anti-rabbit IgG, Alexa Fluor
  488 goat anti-rat IgG or don-
key anti-goat IgG, Alexa Fluor 350 goat anti-rabbit IgG and
Alexa Fluor
  546 goat anti-rat IgG were purchased from
Molecular Prove Inc and used at a ﬁnal concentration of
1:200. Frozen tissue sections were desiccated completely at
room temperature using a dryer, washed with PBS thrice for
5 min each and soaked in PBS containing 5% BSA once for
5 min, then incubated overnight with the primary antibod-
ies. The sections were then washed with PBS thrice for
5 min each and incubated with the Alexa Fluor
  conjugated
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for 5 min each with PBS and mounted on glass slides from
an Anti-fade Kit (Molecular Prove Inc). Positive cells in the
liver were observed using a Provis microscope (Olympus,
Tokyo, Japan) equipped with a charge coupled device cam-
era. A total of 10 different areas in each liver section were
analysed independently.
Quantitative analysis of liver ﬁbrosis
The degree of liver ﬁbrosis was quantiﬁed by measuring
the relative areas of ﬁbrosis with the aid of computer soft-
ware, as described previously (Watanabe et al. 2000).
Brieﬂy, areas were selected at random and assessed using
meta-morph software (Universal Imaging Corporation,
Downingtown, PA, USA) at a magniﬁcation of ·40. The
mean value of six randomly selected areas per sample was
used to evaluate the degree of liver ﬁbrosis, with liver
ﬁbrosis on day 0 determined to be the standard value of
ﬁbrosis index (F.I.) 1.0.
Statistical analysis
Data are presented as the mean ± SD. Differences between
groups were analysed by Student’s t-test, with P < 0.05 con-
sidered to be signiﬁcant.
Results
Presence of ES-derived cells in CCl4-treated livers
Transplantation was performed after pretreatment with
CCl4 for 4 weeks. GFP-immunopositivity in the liver speci-
mens was examined on day 1, as well as at W1, W2, W4,
W8 and W12 in the group 1 mice (Figure 2). There were a
number of GFP-immunopositive cells in the livers of group 1
mice on day 1. Thereafter, although the numbers of those
cells decreased, they remained in the livers throughout the
duration of the experiment. The distribution of immunoreac-
tivity against GFP was observed predominantly in the peri-
portal regions of the hepatic lobules.
Decreased ﬁbrosis following ES transplantation
Liver ﬁbrosis was evaluated histologically using picro-Sirius
red and Mallory-azan staining. Pretreatment with CCl4 for
4 weeks caused considerable liver ﬁbrosis (Figure 3a, top). In
group 2 mice, which received PBS instead of ES cells, liver
ﬁbrosis continuously progressed following treatment with
CCl4 (Figure 3a, group 2). When compared with group 2
mice, reduced liver ﬁbrosis was observed in group 1
(Figure 3a, group 1). The results of quantitative evaluations
using an image analyser are shown in Figure 3b. A signiﬁcant
reduction in liver ﬁbrosis was observed in group 1 as com-
pared with group 2 at all observation points except W12.
GFP-immunopositive cells in locations neighbouring
ﬁbrosis areas
The location of GFP-immunopositive cells was determined
using liver specimens from group 1 mice taken at W1, W4,
W8 and W12 (Figure 4). GFP-immunopositive cells were




































































Experiment  Experiment 1  1 
Experiment  Experiment 2  2 
(n = 4) 
Group 2 
(n = 24) 
: 1×105 ES cells / 0.1 ml 
: 0.1 ml PBS
: Euthanize 4 mice each
Figure1 Grouping of experimental animals and outline of the
experiments. Female C57BL⁄6 mice (n = 56) received CCl4
treatment for 4 weeks, after which four mice were killed, which
was designated as day 0. The remaining 52 mice were divided
into group 1 (n = 28) and group 2 (n = 24). Group 1 received
transplantation of 1 · 10
5 graft cells on day 0 and group 2 were
injected with 0.1 ml of PBS. Liver sampling was performed at
W1, W2, W4, W8 and W12 using four mice from each group,
as well as on day 1 in group 1 only. At W12, the remaining
four mice in group 1 received a second transplantation of graft
cells and those in group 2 received 0.1 ml of PBS into the
spleen. All were then subjected to an additional 4 weeks of
treatment with CCl4.
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livers
To explore the mechanism of ﬁbrolysis, we examined the
expression of MMP9 immunohistochemically using liver
specimens from group 1 mice taken at W12 (Figure 5a–c). As
expected, the transplanted cells expressed MMP9
(Figure 5a–c, arrows). Further, there were some cells
immunopositive for MMP9 that were not immunopositive for
GFP (Figure 5a–c, arrowheads), indicating that they had
originated from the recipient mice. Our results suggest that
not only transplanted ES-derived cells, but also endogenous
ﬁbrolysis activities contributed to improved liver ﬁbrosis.
Although MMP9 is known to be expressed in alveolar macro-
phages in the lung (Figure 5d,h), no expression of F4⁄80, a
marker of macrophages, was found in GFP-immunopositive
cells in the liver (Figure 5e–g arrows). There were some cells
immunopositive for F4⁄80 in the liver, although they were not
immunopositive for GFP (Figure 5e–g arrowheads).
We also investigated the expression of DLK to eluci-
date the characteristics of the cells that were MMP9-
immunopositive and F4⁄80-negative. DLK is a molecule
identiﬁed as a possible hepatoblast marker and known to be
strongly expressed on hepatoblasts in mouse embryonic
livers until embryonic day 16.5, after which it becomes
downregulated and disappears by birth (Tanimizu et al.
2003). Interestingly, MMP9-immunopositive cells, irrespec-
tive of their origin from graft cells or the recipient, were
Figure 3 Decreased ﬁbrosis by ES transplantation. (a) Liver
histology ﬁndings on day 0, and at post-transplantation at W1,
W2, W4, W8 and W12. Presumable liver ﬁbrosis was induced
by 4 weeks of treatment with CCl4. In group 2 mice, which
received PBS, liver ﬁbrosis continuously progressed, whereas
that was reduced in group 1 mice, which received ES cell grafts.
(b) Quantitative evaluation of liver ﬁbrosis using image analy-
ser. Fibrosis reduction was observed in group 1 (closed squares)
as compared with group 2 (open squares) (*P < 0.05). In a
comparison with liver ﬁbrosis on day 0, reductions were con-
ﬁrmed at W1 and W2 in group 1 using picro-Sirius red staining
and at W1 using Mallory-azan staining (
#P < 0.05). Liver ﬁbro-






Figure2 Presence of ES-derived cells in CCl4-treated livers.
GFP-immunopositivity was examined in liver specimens from
group 1 mice on day 1, then at W1, W2, W4, W8 and W12.
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heads respectively), indicating that they were hepatoblast-
like cells.
Liver ﬁbrosis improved by secondary ES cell
transplantation
At W12, the remaining four mice in group 1 received a
second transplantation of ES cells into the spleen, while
those in group 2 received 0.1 ml of PBS, after which mice
in both groups were subjected to an additional 4 weeks of
treatment with CCl4. However, all mice in group 2 died
no later than W15 and exhibited ascites before death,
leading us to conclude that the cause of death was liver
failure. The livers were isolated within 8 h after death and
W1 W4
W12 W8
Figure 4 GFP-immunopositive cells in locations adjacent to
ﬁbrosis areas. GFP-immunopositive cells were found adjacent to




















Figure 5 Immunoﬂuorescence analyses. (a–d) GFP and MMP9-
immunopositive ﬁndings were examined using liver specimens
from group 1 mice taken at W12 (a–c) and specimens from nor-
mal C57BL⁄6 mice at 6 weeks of age (d). GFP-immunopositive
cells were also MMP9-immunopositive (arrows), while some
MMP9-immunopositive cells were not positive for GFP (arrow-
heads). Abundant immunopositivity for MMP9 was observed in
the lung. Bar = 40 lm. (e–h) Immunopositivity for GFP and
F4⁄80, a marker of macrophages, was examined using liver
specimens from group 1 mice taken at W12 (e–g) and from nor-
mal C57BL⁄6 mice at 6 weeks of age (h). GFP-immunopositive
cells were negative for F4⁄80 (arrows), while F4⁄80-immuno-
positive cells were not positive for GFP (arrowheads). Abundant
immunopositivity for F4⁄80 was observed in the lung.
Bar = 40 lm. (i–l) Immunopositivity for MMP, GFP and DlK-1
was examined using liver specimens from group 1 mice taken at
W12. MMP-immunopositive cells (arrows and arrowheads,
magniﬁed in insets), derived from ES cells (arrows) and resident
liver cells (arrowheads), were positive for DlK-1. P, portal vein;
bar = 40 lm.
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second transplantation (W16) showed reduced ﬁbrosis as
compared with W12 (Figure 6a), which was determined
quantitatively by image analysis (Figure 6b). In group 2,
histological ﬁndings of the liver showed advanced ﬁbrosis
with lipid accumulation, although there was no signiﬁcant
difference between W12 and W16.
Tumour formation
All of the livers in the experimental animals were removed
and the lobes sliced into 2-mm widths, with specimens from
the middle lobes used for microscopic analysis. No tumour
formation was observed macroscopically or microscopically
in any of the livers and spleens. Organs other than the liver
and lungs were found to be macroscopically intact.
Discussion
Recently, transplantation of bone marrow cells (Sakaida
et al. 2004), bone marrow stem cells (Wu et al. 2005), bone
marrow mesenchymal stem cells (Fang et al. 2004; Zhao
et al. 2005; Oyagi et al. 2006) and foetal liver progenitor
cells (Zheng et al. 2006) has been reported to reduce liver
ﬁbrosis. However, the effect of ES cells on liver ﬁbrosis has
not been reported. We previously reported that ES cells
transplanted into the spleens of CCl4-treated mice migrated
to the liver and differentiated into hepatocyte-like cells
(Moriya et al. 2007). In that study, we also noted the possi-
bility that ES cells might reduce ﬁbrosis of the liver,
although the total experimental period was only 5 weeks,
which consisted of a 1-week pretreatment with CCl4 before
intrasplenic transplantation of ES cells and then an addi-
tional 4 weeks of treatment. In this study, we conducted a
long-term experiment to examine the effects of ES cell trans-
plantation on liver ﬁbrosis. Mice were pretreated with CCl4
for 4 weeks to produce considerable liver ﬁbrosis prior to
transplantation, then ﬁbrosis was observed histochemically
for up to 16 weeks after the initial transplantation.
As expected, obvious ﬁbrosis was induced in the livers by
pretreatment with CCl4. First, we determined whether the
transplanted ES cells migrated to and were retained in the
liver for a sustained period, because we noted only few
grafted cells at 30 days after transplantation in mouse livers
in a previous experiment (Moriya et al. 2007). In this study,
we found a considerable number of transplanted cells in the
liver even at W12. These contrasting results were probably
because of the length of the CCl4 pretreatment protocol,
which consisted of two intraperitoneal injections over
1 week in the previous study, whereas we gave eight injec-
tions of CCl4 over a 4-week period in this study. We consid-
ered that a more favourable microenvironment might be
induced in the liver by the present repeated CCl4 administra-
tion, under which ES cells were able to migrate to and reside
in the liver. Recently, the CXCR4⁄SDF1 system has been
suggested to be involved in the migration of bone marrow
cells to inﬂamed organs (Dalakas et al. 2005), including
CCl4-treated livers (Kollet et al. 2003; Jung et al. 2006; Son
et al. 2006). Although the involvement of the CXCR4⁄SDF1
axis in hepatic migration of ES cells transplanted into the
spleen is unknown, we noted a much higher level of SDF1
expression immunohistochemically in the livers of mice
pretreated with CCl4 for 4 weeks as compared with those
pretreated for 1 week (data not shown).
These results demonstrated that transplantation of ES cells
improves liver ﬁbrosis, while immunohistochemistry ﬁndings
also revealed GFP-immunopositive cells in locations neigh-
bouring areas of ﬁbrosis at all observation time-points. Bone
marrow cells and bone marrow-derived mesenchymal stem
cells have been reported to migrate to ﬁbrosis areas of the
liver and show activities of matrix metalloproteinases after
transplantation (Kollet et al. 2003; Sakaida et al. 2004;
Higashiyama et al. 2007). It is conceivable that ES cells elicit
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Figure6 Liver ﬁbrosis improved by second ES cell transplanta-
tion. (a) Liver histology results for group 1 mice at W16 and
group 2 at death. At W12, the remaining four mice in each
group received a second transplantation of ES cells (group 1) or
PBS (group 2) into the spleen. The mice in group 1 survived until
W16, whereas all in group 2 died by W15. (b) Quantitative eval-
uation of liver ﬁbrosis using image analyser. Liver ﬁbrosis was
improved at W16 in group 1. Closed and open squares show
group 1 and group 2 respectively. Liver ﬁbrosis on day 0 was
determined to be the standard value of Fibrosis Index (F.I.) 1.0.
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expected, ES-derived cells in the present livers were immuno-
positive for MMP9, some of which were negative for GFP.
These ﬁndings suggest that the improvement in liver ﬁbrosis
after transplantation of ES cells was a result of ﬁbrolysis activ-
ities by both ES-derived and recipient-derived cells. Next, we
attempted to identify the nature of the MMP9-immunoposi-
tive cells. As the GFP-immunopositive cells were negative for
F4⁄80, we considered that the ES-derived MMP9-immuno-
positive cells were also negative for F4⁄80. Interestingly,
MMP9-immunopositive cells, irrespective of their origin from
ES cells or the recipient, were immunopositive for DlK-1, a
hepatoblast marker (Tanimizu et al. 2003), suggesting that
hepatoblast-like cells play an important role in the regression
of liver ﬁbrosis. Investigation of the pathophysiology of the
generation of MMP9-expressing hepatoblast-like cells from
ES cells and liver resident cells in CCl4-injured livers may lead
to discovery of a new treatment approach for liver ﬁbrosis.
We performed a second transplantation of ES cells at
W12, which led to an additive effect for improved ﬁbrosis
seen at W16. All four mice in group 1 that received ES cell
transplantation twice, day 0 and W12, survived to the ﬁnal
observation point at W16. However, none of the mice that
received PBS instead of ES cells at the same time-points sur-
vived to W16, but rather showed accumulated ascites, lead-
ing us to conclude that the cause of death was liver failure.
Thus, these ﬁndings suggest the potential usefulness of ES
cell transplantation to treat liver cirrhosis.
Recently, a novel trial of intravenous transplantion of
autologous bone marrow-derived stromal cells (BMSCs) in
patients with liver cirrhosis reported improved serum albu-
min and total protein levels (Terai et al. 2006). In contrast
to that method, the present ES cells used as grafts and host
mice were an allogeneic combination, as the cells were
derived from 129SvJ mice and transplanted into C57BL⁄6
mice. In the future, it is considered that human ES cells used
in therapeutic strategies will likely be allogeneic to the host,
except in cases where ES cells are produced with a nuclear
transfer technique using nuclei from the host cells (Lavoir
et al. 2005 or by introducing four recently identiﬁed genes
into host somatic cells (Takahashi et al. 2007; Yu et al.
2007). Although a high incidence of teratomas in livers was
reported following syngeneic transplantation of undifferenti-
ated ES cells and differentiating EBs into C57BL⁄6 mice
receiving CCl4 treatment (Chinzei et al. 2002; Yamamoto
et al. 2003), we found no tumours in the livers of mice that
received undifferentiated allogeneic ES cells during the 16-
week experimental period.
In conclusion, our results showed that undifferentiated ES
cells grafted into the spleen migrated to the liver and
reduced liver ﬁbrosis in mice chronically treated with CCl4.
For the coming era of controlled cell growth, ES cells are a
promising cell source for treatment of liver cirrhosis.
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